Home | Publications | Therapeutic | Vaccines place holder
place holder place holder

Vaccines

The Antivirals Market Outlook

Market analysis of future growth and leading players by sector

Publication Date   January 2005
Publisher   Business Insights
Product Type   Report
Pages   178
ISBN Number   not applicable
Product Code   RBI033
Ask a question about this product?

Price £1,495.00

approximately: $2,640 | €1,896

Summary


Business Insights have teamed up with IMS Health to bring you, 'The Antivirals Market Outlook: Market analysis of future growth and leading players by sector.' This unique product offering provides an analysis of changing market conditions and strategic future outlook using the gold standard IMS Health sales data, an unrivalled source of pharmaceutical intelligence on the Antivirals market. 'The Antivirals Market Outlook: Market analysis of future growth and leading players by sector', analyzes the market development in the US and the five major European markets. The major therapy areas covered in this report are: HIV, hepatitis, herpes, influenza, RSV and HPV. For each market therapy area there is a country-by-country analysis, a review of leading companies and an analysis of key brands allowing you to assess the best pipeline areas to invest in. Identify unmet needs and growth opportunities in each market by reviewing pipeline drugs with the most potential for profit for your company.

Content


  • Executive Summary
    • Overview Of Antiviral Drug Therapies
    • Hiv
    • Herpes (Hsv, Vzv & Cmv)
    • Hepatitis B & C
    • Other Viral Infections
  • Chapter 1 Overview Of Antiviral Drug Therapies
    • Summary
    • Introduction
    • Viral Infections
    • Hiv
    • Herpes Viruses
    • Hsv-1 And Hsv-2
    • Vzv
    • Cmv
    • Hepatitis
    • Hepatitis B
    • Hepatitis C
    • Influenza
    • Respiratory Syncytial Virus
    • Human Papillomavirus
    • The European And Us Antiviral Market
    • Antivirals As Part Of Anti-Infectives Market
    • Antiviral Market Segments
    • Leading Antiviral Brands
    • Key Players
    • Growth Drivers And Resistors
    • Common Growth Drivers
    • Common Growth Resistors
  • Chapter 2 Hiv
    • Summary
    • Introduction
    • Epidemiology Analysis
    • Disease Description
    • Diagnosis And Treatment
    • Increasing Lifespan
    • Continued Resistance Development
    • Patient Population
    • Rises In New Infections
    • Market Analysis
    • History Of Hiv Antiviral Drug Development
    • Market Overview
    • Nrti Drug Analysis
    • Combivir
    • Trizivir
    • Viread
    • Epivir (3tc)
    • Zerit (D4t)
    • Ziagen (Abc)
    • Videx & Videx Ec
    • Newly Approved Nrti Combination Pills
    • Nnrti Drug Analysis
    • Sustiva
    • Viramune
    • Pi Drug Analysis
    • Kaletra
    • Viracept
    • Invirase & Fortovase
    • Crixivan
    • Reyataz
    • Ei Drug Analysis
    • Fuzeon
    • Country Focus
    • Key Players
    • Gsk
    • Bms
    • Abbott
    • Gilead
    • R&d Pipeline Analysis And Future Trends
    • Nrtis
    • Reverset (Dpc-817)
    • Racivir (Psi5004)
    • Miv-310 (Flt/Alovudine)
    • Elvucitabine (Ach-126, 443/Beta-L-Fd4c)
    • Spd-754 (Bch-10618/52)
    • Other Developmental Nrtis
    • Discontinued Programs
    • Nnrtis
    • Capravirine (Ag1549/S1153)
    • Tmc-125 (Etravirine)
    • Calanolide A
    • Other Developmental Nnrtis
    • Discontinued Programs
    • Pis
    • Tipranavir (Pnu-140690)
    • Tmc-114
    • Other Developmental Pis
    • Eis
    • Sch-D (Sch-417690)
    • UK-427, 857
    • Gsk-873140
    • Amd-070
    • Other Developmental Eis
    • Discontinued Programs
    • Forecasts To 2010
  • Chapter 3 Herpes (Hsv, Vzv & Cmv)
    • Summary
    • Introduction
    • Epidemiology Analysis
    • Hsv
    • Disease Description
    • Diagnosis And Treatment
    • Patient Population
    • Vzv
    • Disease Description
    • Diagnosis And Treatment
    • Patient Population
    • Cmv
    • Disease Description
    • Diagnosis And Treatment
    • Patient Population
    • Market Analysis
    • Market Overview
    • Hsv & Vzv Antiviral Drug Analysis
    • Zovirax
    • Valtrex/Zelitrex
    • Denavir
    • Famvir
    • Abreva
    • Cmv Antiviral Drug Analysis
    • Cytovene
    • Valcyte
    • Country Focus
    • Key Players
    • R&d Pipeline Analysis And Future Trends
    • Me-609
    • Rp-606
    • Pcl-016
    • Doxovir
    • Discontinued Programs
    • Forecasts To 2010
  • Chapter 4 Hepatitis B & C
    • Summary
    • Introduction
    • Epidemiology Analysis
    • Hepatitis B
    • Disease Description
    • Diagnosis And Treatment
    • Patient Population
    • Hepatitis C
    • Disease Description
    • Diagnosis And Treatment
    • Patient Population
    • Market Analysis
    • Market Overview
    • Interferons
    • Immunomodulators
    • Antivirals
    • Hbv Antiviral Drug Analysis
    • Hepsera
    • Zeffix/Epivir-Hbv
    • Hcv Antiviral Drug Analysis
    • Rebetol & Rebetron
    • Copegus
    • Key Players
    • R&d Pipeline Analysis And Future Trends
    • Hbv
    • Emtricitabine (Ftc, Emtriva)
    • Entecavir
    • Telbivudine (Ldt)
    • Other Developmental Hbv Compounds
    • Discontinued Programs
    • Hcv
    • Biln 2061
    • Isis 14803
    • Merimepodib
    • Nm283
    • Other Developmental Hcv Compounds
    • Forecasts To 2010
  • Chapter 5 Other Viral Infections
    • Summary
    • Introduction
    • Influenza
    • Introduction
    • Epidemiology Analysis
    • Diagnosis And Treatment
    • Patient Population
    • Market Analysis
    • Tamiflu & Relenza Drug Analysis
    • Key Players
    • R&d Pipeline Analysis And Future Trends
    • Forecasts To 2010
    • Respiratory Syncytial Virus (Rsv)
    • Introduction
    • Epidemiology Analysis
    • Diagnosis And Treatment
    • Patient Population
    • Market Analysis
    • Virazole Drug Analysis
    • Key Players
    • R&d Pipeline Analysis And Future Trends
    • Forecasts To 2010
    • Human Papillomavirus (Hpv)
    • Introduction
    • Epidemiology Analysis
    • Diagnosis And Treatment
    • Patient Population
    • Market Analysis
    • R&d Pipeline Analysis And Future Trends
    • Polyphenon E
    • Mbi 1121
    • Other Developmental Hpv Compounds
    • Index
  • List Of Figures
    • Figure 1.1: Us/European* Antiviral Sales ($M), 1999-2003
    • Figure 1.2: Us/European* Shares Of The Antiviral Therapy Areas, 2003
    • Figure 1.3: Market Shares Of The Key Players In Us/European* Antiviral Market (% Value),
    • Figure 2.4: Hiv Subtype Distribution In African Countries, 1996-2001
    • Figure 2.5: Hiv/Aids Disease Progression
    • Figure 2.6: Aids Cases Per Year, 1993-2003
    • Figure 2.7: Geographical Distribution Of Hiv Population, End 2003
    • Figure 2.8: Number Of Hiv Infected Individuals, End 2003
    • Figure 2.9: Timeline Of Hiv Antiviral Development, 1987-2003
    • Figure 2.10: Us/European* Market Share Of Hiv Antiviral Categories (% Value), 1999-2003
    • Figure 2.11: Leading Us/European* Companies In Hiv Antivirals (% Value), 1999-2003
    • Figure 3.12: New Diagnoses Of Genital Herpes, Gum Clinics UK*, 1995-2003
    • Figure 3.13: Us Incidence Of Shingles By Age
    • Figure 3.14: Us/European* Market Share Of Herpes Antivirals, 2002-2003
    • Figure 3.15: Leading Us/European* Companies In Herpes Antivirals (% Value), 1999-2003
    • Figure 4.16: Hbv Disease Progression
    • Figure 4.17: Hbv Population, 2002
    • Figure 4.18: Incidence Of Hbv Infection In The Us, 1982-2003
    • Figure 4.19: Hcv Disease Progression
    • Figure 4.20: Hcv Population, 2002
    • Figure 4.21: Incidence Of Hcv Infection In The Us, 1982-2003
    • Figure 4.22: Us/European* Sales Of Hepatitis Products By Drug Class (% Value), 1999-2003
    • Figure 4.23: Us/European* Market Share Of Hepatitis B & C Antivirals, 2002-2003
    • Figure 4.24: Leading Us/European* Companies In Hepatitis (Hbv & Hcv) Market (% Value), 1999-2003
    • Figure 5.25: Seasonal Variation In Influenza Infection, England, 1999-2004
    • Figure 5.26: Number Of Deaths From Influenza And Pneumonia In The Us, 1995-2002
    • Figure 5.27: Leading Global* Companies In Influenza Antivirals, 1999-2003
    • Figure 5.28: Laboratory Reports To The Communicable Disease Surveillance Centre Of Infections Due To Rsv In England And Wales, 1993-2004 (4 Weekly)
    • Figure 5.29: Estimated Number Of Deaths In The Us Attributable To Rsv, By Age Group, 1990-
    • Figure 5.30: Leading Us/European* Companies In Rsv Products (% Value), 1999-2003
    • Figure 5.31: Number Of New Diagnoses Of Genital Warts, Gum Clinics UK*, 1995-2003
    • Figure 5.32: Timeline For The Launch Of Developmental Hpv Treatments, 2006-2015
  • List Of Tables
    • Table 1.1: Common Herpes Viruses And Infections Caused
    • Table 1.2: Share Of Antiviral Segment In Anti-Infectives Market, Us/Europe*, 2002-2003
    • Table 1.3: Us/European* Sales Value Of Antiviral Market Segments ($M), 2002-2003
    • Table 1.4: Us/European* Sales And Market Shares Of The Top 20 Antiviral Drugs ($M), 2003
    • Table 2.5: Geographic Breakdown Of The Hiv Infected Population, 2003
    • Table 2.6: Leading Us/European* Nrtis ($M), 2002-2003
    • Table 2.7: Sales Of Leading Us/European* Nnrtis, ($M) 2002-2003
    • Table 2.8: Leading Us/European* Pis ($M), 2002-2003
    • Table 2.9: Leading Us/European* Eis ($M), 2002-2003
    • Table 2.10: Sales Of Hiv Antivirals By Country ($M), 2002-2003
    • Table 2.11: Nrti Pipeline Products, 2004
    • Table 2.12: Nnrti Pipeline Products, 2004
    • Table 2.13: Pi Pipeline Products, 2004
    • Table 2.14: Ei Pipeline Products, 2004
    • Table 1.15: Us/European* Sales Forecasts For Hiv Drugs ($M), 2007 & 2010
    • Table 3.16: Prevalence Of Hsv In The Us, 2004
    • Table 3.17: Population At High-Risk Of Cmv Infection, 2002
    • Table 3.18: Global* Sales Of Leading Herpes Antivirals ($M), 2002-2003
    • Table 3.19: Sales Of Herpes Antivirals By Country ($M), 2002-2003
    • Table 3.20: Herpes Pipeline Products, 2004
    • Table 3.21: Us/European* Sales Forecasts Of Herpes Antivirals ($M), 2007 & 2010
    • Table 4.22: Us/European* Sales Of Leading Hepatitis Products ($M), 2002-2003
    • Table 4.23: Sales Of Hepatitis Products By Country ($M), 2002-2003
    • Table 4.24: Hbv Pipeline Products, 2004
    • Table 4.25: Hcv Pipeline Products, 2004
    • Table 4.26: Us/European* Sales Forecasts Of Hbv/Hcv Drugs ($M), 2007 & 2010
    • Table 5.27: Us/European* Sales Of Influenza Antivirals ($M), 2002-2003
    • Table 5.28: Us/European* Sales Of Rsv Products ($M), 2002-2003
    • Table 5.29: Rsv Developmental Pipeline, 2004
    • Table 5.30: Us/European*Forecast Sales Of Rsv Products ($M), 2007 & 2010 166